Expanded knowledge of the pathogenesis behind diseases has led to the development of novel treatment strategies. Functional and molecular imaging modalities are promising for non-invasive diagnosis and evaluation of treatment response at an earlier time point than morphological imaging. The goals are to individualize diagnostic work-up and treatment, in order to optimize treatment outcome and minimize toxicity. The group focuses on:

• clinical- and translational studies
• how to optimize image quality and to improve accuracy of disease detection
• in vivo tissue characterization and depiction of disease process
• treatment response assessment
• multimodality imaging
• targeted radionuclide therapies
• theranostic medicine
• radiomics and artificial intelligence

• Multimodal imaging in the characterization of tumors to assess tumor aggressiveness, diagnostic work-up and treatment response evaluation in prostate cancer, cervical cancer, breast cancer, sarcomas, spinal metastases, neuroendocrine tumors, GISTs, colorectal cancers, liver malignancies, multiple myeloma and lymphoma
• Characterization of vascular inflammation inclusive vulnerability in atherosclerosis, treatment selection and treatment response evaluation using PET, MRI and US
• Detection and treatment response evaluation in inflammatory and fibrosing diseases using different imaging modalities and PET tracers
• Characterize pituritary microadenomas, remnant adenomas following surgery and hypophysitis by the use of different MRI and PET techniques
• Radionuclide therapies for treatment of non-Hodgkin lymphoma, neuroendocrine tumors (NET) and Selective Internal Radiation Therapy (SIRT) 
• Development and testing of novel radionuclide therapies with emphasis on alpha-emitters
• Molecular imaging and quantification of neurological diseases
• Ultrasound-guided percutaneous ethanol injection treatment in patients with metastatic lymph nodes from thyroid carcinoma
• Development of new biomarkers using radiomics and artificial intelligence (AI) for the characterization of diseases

Contact information

Group leader Eivor Hernes, consultant, researcher; MD, PhD
Div.of Radiology and Nuclear Medicine (KRN) OUS
E-mail: EHH@ous-hf.no